Back

Efficacy and safety of SGLT2 inhibitors in acute heart failure: a systematic review and meta-analysis of randomized controlled trials

17 May 2025 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: ePosters in chronic heart failure - pharmacotherapy (3) Pharmacotherapy HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Mr Sebastian Fox

Birmingham (United Kingdom of Great Britain & Northern Ireland)

8 More presentations in this session

Presentation thumbnail
Assessment of pharmacotherapy modifications during the treatment of episode of acutely decompensated heart failure - the HEROES study.
Doctor A. Galas (Warsaw, PL)
Abstract Slides Video
Presentation thumbnail
Vericiguat and reverse ventricular remodeling in patients with chronic HFrEF and recent heart failure worsening
Doctor T. Bajec (Ljubljana, SI)
Abstract Slides Video
Presentation thumbnail
Optimising heart failure therapy: potassium binders and the initiation and titration of mineralocorticoid receptor antagonists
Doctor T. Furlan (Trbovlje, SI)
Abstract Slides Video
Presentation thumbnail
Performance of mortality risk scores in advanced heart failure patients: a retrospective cohort study
Doctor C. Gregorio (Lisbon, PT)
Abstract Slides Video
Presentation thumbnail
Diuretic discontinuation after heart failure hospitalisation
Doctor J. Matejka (Pardubice, CZ)
Abstract Slides Video

Access the full session

Session thumbnail
ePosters in chronic heart failure - pharmacotherapy (3)

The Event

Event poster

Heart Failure 2025

17 May - 20 May 2025
You may be interested in
thumbnail
Congress Presentation
Initiation of sodium-glucose co-transporter-2 inhibitors in patients with heart failure in the acute medical setting
thumbnail
Congress Presentation
Safety and efficacy of early initiation of sodium-glucose co-transporter inhibitors 2 in patients hospitalized for acute heart failure: a meta-analysis of randomized controlled trials
thumbnail
Congress Presentation
Initiation of SGLT2I during acute HF hospitalization or in the immediate period following discharge.

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources